Schönitzer D, Frisch H
Padiatr Padol. 1984;19(3):263-78.
The frequency of the haemolytic disease of the newborn due to ABO-incompatibility (ABO-HDN), requiring treatment, is with approximately 5% of all hyperbilirubinemias in newborns lower than usually expected. Contrary to common conception the serologic diagnosis of ABO-HDN by means of the direct antiglobulin test (DAT) is possible with satisfactory accuracy. The enormous laboratory burden of IgG-anti-A, -B testing during pregnancy is in poor conformity with clinically demonstrable illness. This discrepancy is due to the rarity of true ABO incompatibilities and not to the ineffectiveness of laboratory investigations.
因ABO血型不合导致的新生儿溶血病（ABO-HDN）需要治疗的频率，在所有新生儿高胆红素血症中约占5%，低于通常预期。与普遍认知相反，通过直接抗球蛋白试验（DAT）对ABO-HDN进行血清学诊断具有令人满意的准确性。孕期进行IgG抗A、抗B检测带来的巨大实验室负担与临床上可证实的疾病情况不太相符。这种差异是由于真正的ABO血型不合情况罕见，而非实验室检测无效。
